Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.16089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia.
J Mol Diagn
November 2024
Department of Pathology and Laboratory Medicine, University of Kentucky HealthCare, University of Kentucky, Lexington, Kentucky. Electronic address:
Accurate monitoring of minimal residual disease (MRD) is crucial for effective management of patients with acute myeloid leukemia (AML). This study aims to validate MRD detection of the seven most common IDH1 and IDH2 mutations in patients with AML using a QuantStudio 3D digital PCR platform. This assay demonstrated a high concordance for the variant allele frequencies between digital PCR and next-generation sequencing assays.
View Article and Find Full Text PDFAML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Front Oncol
October 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Article Synopsis
- Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
- A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
- The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
The Leukemic Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs).
Cancers (Basel)
July 2024
Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy.
How hematopoietic stem and progenitor cell (HSPC) fate decisions are affected by genetic alterations acquired during AML leukemogenesis is poorly understood and mainly explored in animal models. Here, we study () gene mutations in the human model of HSPC and discuss the available literature on this topic. mutations occur in ~20% of AML cases, are recognized among the mutations earliest acquired during leukemogenesis, and are targets of specific inhibitors (ivosidenib and enasidenib, respectively).
View Article and Find Full Text PDF: a computational study of enasidenib resistance due to IDH2 mutations.
Phys Chem Chem Phys
July 2024
Department of Chemistry and Biomedical Sciences, Linnaeus University, SE-391 82 Kalmar, Sweden.
Isocitrate dehydrogenase 2 (IDH2) is a homodimeric enzyme that plays an important role in energy production. A mutation R140Q in one monomer makes the enzyme tumourigenic. Enasidenib is an effective inhibitor of IDH2/R140Q.
View Article and Find Full Text PDFRationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
Bioorg Chem
August 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza 12566, Egypt. Electronic address:
Article Synopsis
- This study introduces new small molecules, specifically substituted 1,3,5-triazines, designed as second-generation inhibitors targeting IDH1 and IDH2, building on the structures of existing drugs like vorasidenib and enasidenib. !* -
- Among the tested compounds, 6b showed significant effectiveness against leukemia cell lines with low micromolar growth inhibition (GI) values and demonstrated superior anti-tumor activity compared to cisplatin in specific cancer cells. !* -
- The candidate 6b exhibited remarkable dual inhibitory potential against IDH1 and IDH2, increased levels of important tumor-suppressing proteins, and resulted in notable tumor reduction and health improvements in a
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!